Lundbeck's experimental drug cuts migraine days in mid-stage trial

• Bocunebart reduced monthly migraine days by an average of 4.24 days versus 2.86 days for placebo over 12 weeks in patients with one to four prior treatment failures
• Pooled data for severe, chronic migraine patients showed a stronger effect with 2.31 more migraine-free days than placebo
• Jefferies analysts forecast peak global sales of $400 million for the drug, which targets the PACAP pathway rather than CGRP used by existing preventative treatments

Summary

Key Development:

Danish pharmaceutical company Lundbeck announced positive mid-stage trial results for bocunebart, an experimental migraine treatment targeting a novel pathway. The drug demonstrated statistically significant reduction in monthly migraine days compared to placebo.

Trial Results:

• In the intravenous trial arm, bocunebart reduced monthly migraine days by an average of 4.24 days (weeks 1-12) versus 2.86 days for placebo
• Placebo-adjusted reduction: 1.38 days in the primary patient group (those with 1-4 prior treatment failures)
• Pooled data for severe, chronic migraine patients showed stronger efficacy: 2.31-day greater reduction versus placebo
• The drug was well-tolerated with no new safety concerns; nasopharyngitis (cold-like symptoms) was the most common adverse event (≥5% of patients)

Market Context:

Bocunebart represents a new treatment approach by targeting the PACAP pathway, distinct from existing CGRP-targeting preventative migraine drugs. This offers potential alternatives for patients unresponsive to current therapies, addressing a significant unmet need in treating one of the world's most common neurological disorders.

Analyst Perspective:

Jefferies analysts had anticipated modest improvement over earlier single-dose studies (which showed 2-day placebo-adjusted reduction over 4 weeks). The firm forecasts peak global sales of $400 million for bocunebart.

Presentation:

Data was presented at the American Headache Society congress in Orlando, Florida on June 4, supporting further clinical development of the drug.